Lentini Renee 4

Accession 0001415889-23-014916

CIK 0000855654other

View on SEC.gov Company Profile

Filed

Nov 7, 7:00 PM ET

Accepted

Nov 8, 5:55 PM ET

Size

31.1 KB

Accession

0001415889-23-014916

Insider Transaction Report

Form 4

Period: 2023-11-06

ImmunoGen, Inc.IMGN

Lentini Renee

V.P.-Fin., Prin. Acctg. Off.

Transactions

Exercise/Conversion
Common Stock
2023-11-06$10.79/sh+9,000$97,110→ 108,017 total
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−4,024→ 12,625 total
Exercise: $6.98Exp: 2031-01-08→ Common Stock (4,024 underlying)
Exercise/Conversion
Common Stock
2023-11-06$7.69/sh+55,550$427,180→ 207,583 total
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−55,550→ 25,250 total
Exercise: $7.69Exp: 2031-02-05→ Common Stock (55,550 underlying)
Exercise/Conversion
Common Stock
2023-11-06$5.25/sh+14,373$75,458→ 148,009 total
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−23,000→ 0 total
Exercise: $10.65Exp: 2028-02-15→ Common Stock (23,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−14,373→ 0 total
Exercise: $5.25Exp: 2029-01-31→ Common Stock (14,373 underlying)
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−11,962→ 53,831 total
Exercise: $5.32Exp: 2032-02-04→ Common Stock (11,962 underlying)
Exercise/Conversion
Common Stock
2023-11-06$2.68/sh+2,619$7,019→ 110,636 total
Exercise/Conversion
Common Stock
2023-11-06$6.98/sh+4,024$28,088→ 152,033 total
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−2,619→ 0 total
Exercise: $2.68Exp: 2026-09-30→ Common Stock (2,619 underlying)
Exercise/Conversion
Common Stock
2023-11-06$10.65/sh+23,000$244,950→ 133,636 total
Exercise/Conversion
Common Stock
2023-11-06$5.32/sh+11,962$63,638→ 219,545 total
Sale
Common Stock
2023-11-06$15.29/sh−219,545$3,356,843→ 0 total
Exercise/Conversion
Stock Option (right to buy)
2023-11-06−9,000→ 0 total
Exercise: $10.79Exp: 2024-07-17→ Common Stock (9,000 underlying)

Footnotes (8)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
[F2]This option was granted on 7/17/2014 and is fully vested as of the transaction date.
[F3]This option was granted on 9/30/2016 and is fully vested as of the transaction date.
[F4]This option was granted on 2/15/2018 and is fully vested as of the transaction date.
[F5]This option was granted on 1/31/2019 and is fully vested as of the transaction date.
[F6]This option was granted on 1/8/2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
[F7]This option was granted on 2/5/2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
[F8]This option was granted on 2/4/2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

Documents

1 file

4
form4-11082023_101139.xmlPrimary

Issuer

ImmunoGen, Inc.

CIK 0000855654

→

Entity typeother

Related Parties

filerCIK 0001838777

Filing Metadata

Form type: 4
Filed: Nov 7, 7:00 PM ET
Accepted: Nov 8, 5:55 PM ET
Size: 31.1 KB

View on SEC.gov